FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2022795891> ?p ?o ?g. }

• W2022795891 endingPage "276" @default.
• W2022795891 startingPage "271" @default.
• W2022795891 abstract "Compared to other statins, pitavastatin is a highly potent 3-hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) reductase inhibitor and an efficient hepatocyte low-density lipoprotein-cholesterol (LDL-C) receptor inducer. Its characteristic structure (heptenoate as the basic structure, a core quinoline ring and side chains that include fluorophenyl and cyclopropyl moieties) provides improved pharmacokinetics and significant LDL-C-lowering efficacy at low doses. Unlike other statins, the cyclopropyl group on the pitavastatin molecule appears to divert the drug away from metabolism by cytochrome P450 (CYP) 3 A4 and allows only a small degree of clinically insignificant metabolism by CYP2C9. As a result, pitavastatin is minimally metabolized; most of the bioavailable fraction of an oral dose is excreted unchanged in the bile and is reabsorbed by the small intestine ready for enterohepatic recirculation. This process probably accounts for pitavastatin's increased bioavailability relative to most other statins and contributes to its prolonged duration of action. In addition to its potent LDL-C-lowering efficacy, a number of pleiotropic benefits that might lead to a reduction in residual risk have been suggested in vitro. These include beneficial effects on endothelial function, stabilisation of the coronary plaque, anti-inflammatory effects and anti-oxidation. With regard to the clinical safety and efficacy of pitavastatin, the Phase IV Collaborative study of Hypercholesterolemia drug Intervention and their Benefits for Atherosclerosis prevention (CHIBA study) showed similar changes in lipid profile with pitavastatin and atorvastatin in Japanese patients with hypercholesterolemia. However, a subgroup analysis of the CHIBA study showed that pitavastatin produced more significant changes from baseline in LDL-C, TG, and HDL-C in patients with hypercholesterolemia and metabolic syndrome. The clinical usefulness of pitavastatin has been further demonstrated in a number of Japanese patient groups with hypercholesterolemia, including those with insulin resistance, low levels of high-density lipoprotein-cholesterol (HDL-C), high levels of C-reactive protein, and chronic kidney disease. Finally, the Japan Assessment of Pitavastatin and AtorvastatiN in Acute Coronary Syndrome (JAPAN-ACS) study showed that pitavastatin induces plaque regression in patients with ACS, which suggests potential benefits for pitavastatin in reducing CV risk." @default.
• W2022795891 created "2016-06-24" @default.
• W2022795891 creator A5003742850 @default.
• W2022795891 date "2011-11-01" @default.
• W2022795891 modified "2023-10-06" @default.
• W2022795891 title "Pitavastatin: An overview" @default.
• W2022795891 cites W110324665 @default.
• W2022795891 cites W1963775229 @default.
• W2022795891 cites W1964056813 @default.
• W2022795891 cites W1970853900 @default.
• W2022795891 cites W1975151125 @default.
• W2022795891 cites W1987967030 @default.
• W2022795891 cites W2000218345 @default.
• W2022795891 cites W2004562704 @default.
• W2022795891 cites W2005785320 @default.
• W2022795891 cites W2019169107 @default.
• W2022795891 cites W2044779420 @default.
• W2022795891 cites W2044947981 @default.
• W2022795891 cites W2045063002 @default.
• W2022795891 cites W2047207059 @default.
• W2022795891 cites W2056530140 @default.
• W2022795891 cites W2057755888 @default.
• W2022795891 cites W2066963386 @default.
• W2022795891 cites W2070396041 @default.
• W2022795891 cites W2071162042 @default.
• W2022795891 cites W2082252581 @default.
• W2022795891 cites W2086313852 @default.
• W2022795891 cites W2089405687 @default.
• W2022795891 cites W2093463971 @default.
• W2022795891 cites W2098946775 @default.
• W2022795891 cites W2138383075 @default.
• W2022795891 cites W2159449551 @default.
• W2022795891 cites W2316243284 @default.
• W2022795891 cites W4210993071 @default.
• W2022795891 cites W52699624 @default.
• W2022795891 doi "https://doi.org/10.1016/s1567-5688(11)70886-8" @default.
• W2022795891 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22152281" @default.
• W2022795891 hasPublicationYear "2011" @default.
• W2022795891 type Work @default.
• W2022795891 sameAs 2022795891 @default.
• W2022795891 citedByCount "48" @default.
• W2022795891 countsByYear W20227958912012 @default.
• W2022795891 countsByYear W20227958912013 @default.
• W2022795891 countsByYear W20227958912014 @default.
• W2022795891 countsByYear W20227958912015 @default.
• W2022795891 countsByYear W20227958912016 @default.
• W2022795891 countsByYear W20227958912017 @default.
• W2022795891 countsByYear W20227958912018 @default.
• W2022795891 countsByYear W20227958912019 @default.
• W2022795891 countsByYear W20227958912020 @default.
• W2022795891 countsByYear W20227958912021 @default.
• W2022795891 countsByYear W20227958912022 @default.
• W2022795891 countsByYear W20227958912023 @default.
• W2022795891 crossrefType "journal-article" @default.
• W2022795891 hasAuthorship W2022795891A5003742850 @default.
• W2022795891 hasConcept C104950815 @default.
• W2022795891 hasConcept C109650736 @default.
• W2022795891 hasConcept C112705442 @default.
• W2022795891 hasConcept C134651460 @default.
• W2022795891 hasConcept C181199279 @default.
• W2022795891 hasConcept C181389837 @default.
• W2022795891 hasConcept C185592680 @default.
• W2022795891 hasConcept C2776692505 @default.
• W2022795891 hasConcept C2776839432 @default.
• W2022795891 hasConcept C2777482532 @default.
• W2022795891 hasConcept C2778163477 @default.
• W2022795891 hasConcept C2779120738 @default.
• W2022795891 hasConcept C526171541 @default.
• W2022795891 hasConcept C55493867 @default.
• W2022795891 hasConcept C62231903 @default.
• W2022795891 hasConcept C71924100 @default.
• W2022795891 hasConcept C98274493 @default.
• W2022795891 hasConceptScore W2022795891C104950815 @default.
• W2022795891 hasConceptScore W2022795891C109650736 @default.
• W2022795891 hasConceptScore W2022795891C112705442 @default.
• W2022795891 hasConceptScore W2022795891C134651460 @default.
• W2022795891 hasConceptScore W2022795891C181199279 @default.
• W2022795891 hasConceptScore W2022795891C181389837 @default.
• W2022795891 hasConceptScore W2022795891C185592680 @default.
• W2022795891 hasConceptScore W2022795891C2776692505 @default.
• W2022795891 hasConceptScore W2022795891C2776839432 @default.
• W2022795891 hasConceptScore W2022795891C2777482532 @default.
• W2022795891 hasConceptScore W2022795891C2778163477 @default.
• W2022795891 hasConceptScore W2022795891C2779120738 @default.
• W2022795891 hasConceptScore W2022795891C526171541 @default.
• W2022795891 hasConceptScore W2022795891C55493867 @default.
• W2022795891 hasConceptScore W2022795891C62231903 @default.
• W2022795891 hasConceptScore W2022795891C71924100 @default.
• W2022795891 hasConceptScore W2022795891C98274493 @default.
• W2022795891 hasIssue "3" @default.
• W2022795891 hasLocation W20227958911 @default.
• W2022795891 hasLocation W20227958912 @default.
• W2022795891 hasOpenAccess W2022795891 @default.
• W2022795891 hasPrimaryLocation W20227958911 @default.
• W2022795891 hasRelatedWork W1581747141 @default.
• W2022795891 hasRelatedWork W1994874022 @default.
• W2022795891 hasRelatedWork W2011332381 @default.
• W2022795891 hasRelatedWork W2038338711 @default.

• next